These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 25671269)

  • 1. High-cost generic drugs--implications for patients and policymakers.
    Kesselheim AS; Alpern JD; Stauffer WM
    N Engl J Med; 2015 Feb; 372(7):686. PubMed ID: 25671269
    [No Abstract]   [Full Text] [Related]  

  • 2. High-cost generic drugs--implications for patients and policymakers.
    Uhl K; Peters JR; Flanagan K
    N Engl J Med; 2015 Feb; 372(7):685-6. PubMed ID: 25671270
    [No Abstract]   [Full Text] [Related]  

  • 3. High-cost generic drugs--implications for patients and policymakers.
    Alpern JD; Stauffer WM; Kesselheim AS
    N Engl J Med; 2014 Nov; 371(20):1859-62. PubMed ID: 25390739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.
    Sinha MS; Curfman GD; Carrier MA
    JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104
    [No Abstract]   [Full Text] [Related]  

  • 5. States sue generic drug makers for alleged price fixing.
    McCarthy M
    BMJ; 2016 Dec; 355():i6764. PubMed ID: 27993771
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug's 5000% price rise puts spotlight on soaring US drug costs.
    McCarthy M
    BMJ; 2015 Sep; 351():h5114. PubMed ID: 26404904
    [No Abstract]   [Full Text] [Related]  

  • 7. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
    Zain S
    Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
    [No Abstract]   [Full Text] [Related]  

  • 8. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 9. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The wake of FTC v. Actavis: practical implications on the pharmaceutical industry.
    Ritter M; Tempesta J; Ragusa P
    Pharm Pat Anal; 2014 Jul; 3(4):345-7. PubMed ID: 25291307
    [No Abstract]   [Full Text] [Related]  

  • 11. Key compliance concerns for the generic pharmaceutical industry.
    Werling K; Enyeart A
    Health Care Law Mon; 2009 Jul; 2009(7):2-6. PubMed ID: 19618761
    [No Abstract]   [Full Text] [Related]  

  • 12. The Eleventh Circuit holds that agreements in which pharmaceutical companies pay generic companies not to compete may be valid.
    Garrigues A
    J Law Med Ethics; 2004; 32(1):181-4. PubMed ID: 15152443
    [No Abstract]   [Full Text] [Related]  

  • 13. The FTC v. Actavis roadmap: a guide to properly applying the rule of reason standard in reverse payment cases.
    Sharkey N
    J Leg Med; 2014; 35(3):445-66. PubMed ID: 25207633
    [No Abstract]   [Full Text] [Related]  

  • 14. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

  • 15. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
    Brockmeier MS
    Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

  • 17. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
    Yvon AM
    Fordham Law Rev; 2006 Dec; 75(3):1883-912. PubMed ID: 17312596
    [No Abstract]   [Full Text] [Related]  

  • 18. On access and accountability--two Supreme Court rulings on generic drugs.
    Boumil MM; Curfman GD
    N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
    [No Abstract]   [Full Text] [Related]  

  • 19. AstraZeneca must pay €52.5m fine for anticompetitive tactics, rules European court.
    Hawkes N
    BMJ; 2012 Dec; 345():e8396. PubMed ID: 23230222
    [No Abstract]   [Full Text] [Related]  

  • 20. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.